September 22, 2020 | Karen Warmkessel
Stuart S. Martin, PhD, Awarded New Endowed Professorship Honoring Internationally Renowned Breast Cancer Researcher Angela H. Brodie, PhD
Martin Also Co-Leads Hormone-Related Cancers Program at University of Maryland
University of Maryland School of BOB体育 (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Stuart S. Martin, PhD, Professor of Pharmacology and Physiology at UMSOM and a nationally recognized breast cancer researcher, has been installed as . The endowed professorship honors the late Angela H. Brodie, PhD, who, with her husband and longtime scientific collaborator, Harry Brodie, PhD, pioneered the development of aromatase inhibitors, a class of hormone-targeting drugs that has changed the face of breast cancer treatment.
Dr. Martin is recognized for groundbreaking research that combines bioengineering and tumor cell biology. He was the first to identify novel molecular targets called 鈥渕icrotentacles鈥� on the surface of circulating tumor cells that may hold the key to preventing cancer metastasis.
鈥淭here is no one more fitting than Dr. Martin to carry on Dr. Angela and Dr. Harry Brodie鈥檚 enduring legacy of scientific discovery and achievement in breast cancer research,鈥� Dean Reece said. 鈥淗is discovery of microtentacles on the surface of breast cancer cells and continuing efforts to explore their role in how cancer spreads could lead to lifesaving new treatments to halt the progression of often-deadly cancers.鈥�
鈥凄谤. Stuart Martin is a phenomenally talented scientist who has already made significant contributions to the field of breast cancer research,鈥� said Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology at UMSOM, and director of the . 鈥淗e is an excellent choice to carry on the Brodies鈥� legacy of translational research 鈥� moving discoveries made in the laboratory into clinical practice for the benefit of patients.鈥�
Dr. Cullen noted the tremendous impact that Drs. Angela and Harry Brodie鈥檚 scientific partnership and subsequent development of aromatase inhibitors has had on the treatment of breast cancer. 鈥�Today, aromatase inhibitors are used worldwide by hundreds of thousands of women per year, saving countless lives,鈥� he said.
Dr. Martin鈥檚 investiture was held on August 27. Among those who took part in the virtual ceremony was Dr. Harry Brodie, who said the creation of the new professorship 鈥渇ills my heart with gratitude.鈥�
A British-born scientist, Dr. Angela Brodie was a Professor of Pharmacology at UMSOM for more 35 years until her retirement as Professor Emeritus in 2016. She died the following year. During the 1970s, she collaborated with her husband, Harry, a chemist who synthesized an early aromatase inhibitor, 4-hydroxyandrostenedione (4-OH-A), which was later marketed as Formestane. She carried on the research after coming to UMSOM in 1979.
鈥凄谤. Martin鈥檚 work represents the best of modern science and the embodiment of the approach Dr. Brodie used to develop aromatase inhibitors, starting from groundbreaking research done on cells in a dish and taking it all the way to a potentially transformational personalized medicine approach for treating breast cancers,鈥� said Scott Thompson, PhD, Professor and Chair, Department of Physiology at UMSOM.
Margaret M. McCarthy, PhD, the James and Carolyn Frenkil Dean鈥檚 Professor and Chair of the Department of Pharmacology at UMSOM, added:
鈥凄谤. Martin鈥檚 research on the role of microtentacles in cancer metastasis holds tremendous promise for preventing the devastating cancer recurrences experienced by so many breast cancer survivors. His innovative talents serve as a perfect complement to the powerful legacy of Harry and Angela in their advancement of lifesaving therapeutics. He is most deserving of this recognition.鈥�
The endowed professorship in the Department of Pharmacology was funded by the Greenebaum Family Foundation. Speaking on behalf of his family at Dr. Martin鈥檚 investiture, Michael Greenebaum said that his late mother, Marlene, was treated with an aromatase inhibitor after her breast cancer recurred. 鈥�The development of the aromatase inhibitor by the Brodies really is what kept my mom alive for many years,鈥� Greenebaum said. He said he views Dr. Martin鈥檚 new professorship as 鈥�passing research from one generation to the next. I can only imagine the breakthroughs and advances that will come about from the research that Dr. Martin is doing.鈥�
, Professor of Chemical and Biomolecular Engineering at the Johns Hopkins University, said of his longtime collaborator, 鈥凄谤. Martin, is by any quantitative, or qualitative, measure, a truly exceptional scientist. He鈥檚 very well established and extremely well respected in the field of cancer research.鈥� He said Dr. Martin has published more than 75 articles in high-caliber scientific journals. 鈥淗is work has been the torchlight for thousands of publications generated by others in the field.鈥�
In addition to his UMSOM appointment, Dr. Martin is the co-leader of the Hormone-Related Cancers Program at UMGCCC, one of 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation.
Dr. Martin received his PhD in biomedical sciences from the University of California, San Diego, after training as a Howard Hughes undergraduate research fellow at the University of Virginia. He completed a Damon Runyon postdoctoral fellowship at Harvard Medical School that combined functional genomic studies with mouse models of breast tumor metastasis, under the mentorship of Dr. Phil Leder. In 2004, Dr. Martin established his laboratory at UMSOM.
In 2010, Dr. Martin was one of only three investigators in the United States recognized with a five-year, $3.5 million Era of Hope Scholar Award from the Department of Defense for his innovative work on breast cancer metastasis. The award is given to exceptionally talented scientists who are considered the "best and the brightest" and have shown high potential for innovation in breast cancer research early in their careers.
Research in Dr. Martin鈥檚 laboratory is currently supported by two R01 grants from the National Cancer Institute, a VA Merit Award, and funding from the METAvivor Foundation, American Cancer Society, Kahlert Foundation, and Maryland Cigarette Restitution Fund Program.
About the University of Maryland School of BOB体育
Now in its third century, the University of Maryland School of BOB体育 was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of BOB体育 and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of BOB体育 works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of BOB体育 has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of BOB体育 has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of BOB体育 and Medical System (鈥淯niversity of Maryland BOB体育鈥�) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of BOB体育 faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of BOB体育 works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
About the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a National Cancer Institute-designated Comprehensive Cancer Center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of BOB体育. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked among the top cancer programs in the nation by U.S. News & World Report. .
Contact
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
(410) 706-5260
Related stories

Tuesday, December 12, 2017
In Memoriam: Longtime Civic Leader and Philanthropist Stewart Greenebaum Passes Away
Stewart Greenebaum, a prominent business and civic leader in Baltimore who dedicated much of his philanthropic work to supporting cancer research, treatment and education, passed away on Sunday, December 10, 2017. He was 81.

Wednesday, June 07, 2017
In Memoriam: Angela Hartley Brodie, Ph.D., Internationally Renowned Breast Cancer Researcher at University of Maryland School of BOB体育
Angela Hartley Brodie, PhD, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of BOB体育, and an internationally recognized scientist whose groundbreaking cancer research is considered among the greatest advances in treating breast cancer, passed away of complications from Parkinson’s disease at her home in Fulton, MD. She was 82.